1. Home
  2. CERT vs CRVS Comparison

CERT vs CRVS Comparison

Compare CERT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Certara Inc.

CERT

Certara Inc.

HOLD

Current Price

$7.75

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.03

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
CRVS
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
CERT
CRVS
Price
$7.75
$14.03
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$11.67
$30.17
AVG Volume (30 Days)
3.7M
1.0M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
48.04
EPS
N/A
N/A
Revenue
$418,838,000.00
N/A
Revenue This Year
$4.18
N/A
Revenue Next Year
$5.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.75
N/A
52 Week Low
$4.45
$4.05
52 Week High
$13.88
$26.95

Technical Indicators

Market Signals
Indicator
CERT
CRVS
Relative Strength Index (RSI) 45.77 50.71
Support Level $6.57 $12.74
Resistance Level $7.44 $14.00
Average True Range (ATR) 0.37 0.69
MACD -0.03 -0.12
Stochastic Oscillator 22.86 49.44

Price Performance

Historical Comparison
CERT
CRVS

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: